Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
 
Zoeken naar met titel:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             223 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1 40 Allogeneic stem cell transplantation in MDS: reduced intensity conditioning and donor lymphocyte infusion Kröger, N.
 2009
 33 S1 p. S28-
1 p.
 artikel
2 27 Assessing the guidelines on iron chelation in MDS – where are we? Gattermann, N.
 2009
 33 S1 p. S22-S23
2 p.
 artikel
3 Author Index 2009
 33 S1 p. S143-S150
8 p.
 artikel
4 6 BMI-1 and AML1 point mutation in the pathogenesis of MDS Kimura, A.
 2009
 33 S1 p. S2-S3
2 p.
 artikel
5 C008 Array-based comparative genomic hybridization as a clinical assay for genomic profiling in the myelodysplastic syndromes: validation by comparison with conventional cytogenetics and fluorescence in situ hybridization Slovak, M.
 2009
 33 S1 p. S35-S36
2 p.
 artikel
6 C024 Association of NQO1 C609T polymorphism with chromosomes 5 and/or 7 abnormalities in patients with MDS/AML Stavropoulou, C.
 2009
 33 S1 p. S45-S46
2 p.
 artikel
7 C012 B7-H1 molecules on blasts from myelodysplastic syndromes are linked to cellular aggressiveness and capable of inducing T-cell apoptosis Kondo, A.
 2009
 33 S1 p. S38-
1 p.
 artikel
8 C034 Biological factors of response to erythropoiesis-stimulating agents in low/int-1 grade MDS Pawlikowska, P.
 2009
 33 S1 p. S51-S52
2 p.
 artikel
9 C002 C-type lectin-like molecule-1 (CLL-1) and lineage infidelity marker expression as assessed by flow cytometry distinguishes normal and aberrant stem cells in myelodysplastic syndromes Westers, T.
 2009
 33 S1 p. S31-S32
2 p.
 artikel
10 C006 Detailed morphologic findings in 2773 patients with myelodysplastic syndromes Germing, U.
 2009
 33 S1 p. S34-
1 p.
 artikel
11 C001 Development of a multiplex PCR assay for the detection of genomic copy number changes in myelodysplastic syndromes Stamatoullas, A.
 2009
 33 S1 p. S31-
1 p.
 artikel
12 C010 Differentially expressed genes of CD34+ between patients with early and advanced myelodysplastic syndrome Belickova, M.
 2009
 33 S1 p. S36-S37
2 p.
 artikel
13 C035 DNA vaccination as immunotherapy adjuvant in MDS Padua, R.
 2009
 33 S1 p. S52-
1 p.
 artikel
14 C016 Expression analysis of proteins involved in the Non Homologous End Joining DNA repair mechanism, in the bone marrow of adult de novo myelodysplastic syndromes Economopoulou, P.
 2009
 33 S1 p. S40-S41
2 p.
 artikel
15 C014 Expression of p53 or cytoplasmic nucleophosmine associated with increased risk of disease progression in myelodysplastic syndrome with isolated del(5q) Jadersten, M.
 2009
 33 S1 p. S39-
1 p.
 artikel
16 C017 Expression of proteins p16INK4a, p53 and Bmi-1 in hematopoietic stem cells of patients with MDS. The role of cellular senescence Constandinidou, I.
 2009
 33 S1 p. S41-S42
2 p.
 artikel
17 C019 Functional abnormalities of neutrophils in patients with myelodysplastic syndromes Papadaki, H.
 2009
 33 S1 p. S43-
1 p.
 artikel
18 C011 Gene methylation, telomere length and activity of telomerase reflect the disease activity in MDS patients and may help to assess an individual risk of patients Cechova, H.
 2009
 33 S1 p. S37-
1 p.
 artikel
19 C013 Genomic aberrations observed in mesenchymal stem cells from 5q-syndrome could be involved in the pathophysiology of the disease Santamaria, C.
 2009
 33 S1 p. S38-S39
2 p.
 artikel
20 26 Chelation therapy: issues and answers: “Prospective studies in chelation therapy” Rose, C.
 2009
 33 S1 p. S22-
1 p.
 artikel
21 C029 HLA-identical umbilical cord blood transplantation from a sibling donor in juvenile myelomonocytic leukemia De Vries, A.
 2009
 33 S1 p. S48-S49
2 p.
 artikel
22 19 Chronic myelomonocytic leukemia Bowen, D.
 2009
 33 S1 p. S15-
1 p.
 artikel
23 C023 HSP90 is overexpressed in high-risk myelodysplastic syndromes and associated with higher expression and activation of Fak Campos, L.
 2009
 33 S1 p. S45-
1 p.
 artikel
24 C032 Is allogeneic hematopoietic cell transplantation a reasonable therapeutic option for elderly (>60 years) patients with de novo myelodysplastic syndromes? Platzbecker, U.
 2009
 33 S1 p. S50-S51
2 p.
 artikel
25 C028 Lenalidomide abrogates the clonal advantage of del(5q) MDS stem cells via alteration of niche interactions Scharenberg, C.
 2009
 33 S1 p. S48-
1 p.
 artikel
26 C022 Lenalidomide treatment modulates proliferation and differentiation of human mesenchymal stromal cells from healthy donors and MDS patients Wobus, M.
 2009
 33 S1 p. S44-
1 p.
 artikel
27 9 Clinical and pathogenetic implications of array-based karyotyping in MDS Maciejewski, J.P.
 2009
 33 S1 p. S5-
1 p.
 artikel
28 C030 Long-term remission of post-transplant MDS/AML by adoptive transfer of allogeneic WT1-specific CD4+ and CD8+ T lymphocytes Kim, Y.
 2009
 33 S1 p. S49-
1 p.
 artikel
29 C031 Maintenance treatment with 5-azacitidine for patients with high risk myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS (MDS-AML) in complete remission (CR) after induction chemotherapy Groevdal, M.
 2009
 33 S1 p. S49-S50
2 p.
 artikel
30 Committees 2009
 33 S1 p. iv-
1 p.
 artikel
31 4 Controlling the “fate” of T cells in MDS List, A.F.
 2009
 33 S1 p. S1-S2
2 p.
 artikel
32 C020 Prevalence of TET2 mutations in MDS Kosmider, O.
 2009
 33 S1 p. S43-S44
2 p.
 artikel
33 C005 Prognostic impact of the proportion of aberrant metaphases in patients with a primary myelodysplastic syndrome Mallo, M.
 2009
 33 S1 p. S33-S34
2 p.
 artikel
34 C003 Proliferative and apoptotic signalling in bone marrow cell subpopulations of myelodysplastic syndromes patients using flow-cytometry technique Santini, V.
 2009
 33 S1 p. S32-
1 p.
 artikel
35 C015 Proteome analysis of platelets from patients with myelodysplastic syndrome shows low expression of proteins required for GPIIb/IIIa function and platelet aggregation Froebel, J.
 2009
 33 S1 p. S40-
1 p.
 artikel
36 C009 Pyrosequencing reveals the quantity of p15INK4b methylation has correlation with cytopenia, marrow blast percentage and survival in myelodysplastic syndromes Lee, D.
 2009
 33 S1 p. S36-
1 p.
 artikel
37 C033 Quantification of phosphoinositidephospholipase C (PI-PLC) beta 1 gene promoter methylation predicts the responsiveness to azacitidine in myelodysplastic syndromes Follo, M.
 2009
 33 S1 p. S51-
1 p.
 artikel
38 C004 Relevance of prognostic factors in different subgroups of myelodysplastic syndromes Kuendgen, A.
 2009
 33 S1 p. S32-S33
2 p.
 artikel
39 C025 Role of lipid signaling pathways in the response to erythropoietin in low risk MDS patients Finell, C.
 2009
 33 S1 p. S46-
1 p.
 artikel
40 C036 The effects of iron overload on hematopoiesis in the mouse Chan, L.
 2009
 33 S1 p. S53-
1 p.
 artikel
41 C027 The in vitro effect of SB-497115 (Eltrombopag) on megakaryopoiesis of patients with low/intermediate-1 IPSS myelodysplastic syndrome Papadaki, H.
 2009
 33 S1 p. S47-S48
2 p.
 artikel
42 C026 The non-peptide thrombopoietin receptor agonist Eltrombopag (SB-497115, Promacta/Revolade) does not stimulate malignant growth of bone marrow cells from patients with acute myeloid leukemia or myelodysplastic syndromes Will, B.
 2009
 33 S1 p. S46-S47
2 p.
 artikel
43 C021 The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1 Ohyashiki, J.
 2009
 33 S1 p. S44-
1 p.
 artikel
44 C018 Unregulated expression of the orphan nuclear receptor NR2F6 in mice initiates myelodysplastic syndrome that can progress to acute leukemia Ichim, C.
 2009
 33 S1 p. S42-S43
2 p.
 artikel
45 C007 Validation of the WHO proposals for the classification of unclassifiable myelodysplastic syndromes Germing, U.
 2009
 33 S1 p. S35-
1 p.
 artikel
46 31 Decitabine in the treatment of higher-risk MDS Steensma, D.P.
 2009
 33 S1 p. S24-S25
2 p.
 artikel
47 39 Developmental therapeutics for MDS List, A.
 2009
 33 S1 p. S27-S28
2 p.
 artikel
48 3 Diagnosis of immune pathophysiology in patients with low-risk MDS Nakao, S.
 2009
 33 S1 p. S1-
1 p.
 artikel
49 14 Disruption of precise gene product expression in myelodysplasia Loken, M.R.
 2009
 33 S1 p. S10-S11
2 p.
 artikel
50 Editorial Board 2009
 33 S1 p. ii-
1 p.
 artikel
51 8 Gene expression profiling in patients with myelodysplastic syndromes, including patients with the del(5q) Boultwood, J.
 2009
 33 S1 p. S3-S4
2 p.
 artikel
52 32 Hypomethylating agents in MDS changing the inevitable: the value of maintenance therapy, effects on transfusions and combination with other agents Silverman, L.R.
 2009
 33 S1 p. S25-S26
2 p.
 artikel
53 15 Identification of prognostic subgroups by flow cytometry in myelodysplastic syndromes van de Loosdrecht, A.
 2009
 33 S1 p. S11-
1 p.
 artikel
54 23 Inherited syndromes and low risk MDS: lessons learned from the Greek Pediatric MDS Registry Polychronopoulou, S.
 2009
 33 S1 p. S18-S19
2 p.
 artikel
55 36 Innovative clinical trial design in MDS Estey, E.
 2009
 33 S1 p. S26-
1 p.
 artikel
56 29 In vitro basis for treatment with hypomethylating agents and HDAC inhibitors: Can epigenetic changes be used to monitor treatment? Gore, S.D.
 2009
 33 S1 p. S24-
1 p.
 artikel
57 28 Iron toxiticity and chelation therapy in allogeneic SCT de Witte, T.
 2009
 33 S1 p. S23-S24
2 p.
 artikel
58 21 Juvenile myelomonocytic leukemia Flotho, C.
 2009
 33 S1 p. S17-
1 p.
 artikel
59 37 Low-risk MDS; transfusion therapy, growth factors and the European view on lenalidomide Hellström-Lindberg, E.
 2009
 33 S1 p. S26-S27
2 p.
 artikel
60 38 Management of del(5q) MDS Giagounidis, A.
 2009
 33 S1 p. S27-
1 p.
 artikel
61 7 Molecular changes as detected by high-throughput genomic techniques in MDS Hofmann, W.-K.
 2009
 33 S1 p. S3-
1 p.
 artikel
62 10 Myelodysplastic syndromes: update on classification Bennett, J.M.
 2009
 33 S1 p. S6-S8
3 p.
 artikel
63 18 Myelodysplastic syndromes with marrow fibrosis Della Porta, M.G.
 2009
 33 S1 p. S14-S15
2 p.
 artikel
64 17 Myelodysplastic syndromes with unilineage cytopenia (neutropenia/thrombocytopenia) Papadaki, H.
 2009
 33 S1 p. S11-S14
4 p.
 artikel
65 P043 Aberrant immunophenotype of blasts in low and intermediate-1 risk myelodysplastic syndromes predicts response to growth factor treatment. A prospective clinical phase II study Westers, T.
 2009
 33 S1 p. S83-
1 p.
 artikel
66 P046 Abnormal expression of C3ORF9 gene in patients with myelodysplastic syndromes Karadonat, A.
 2009
 33 S1 p. S85-
1 p.
 artikel
67 P052 Acquired mutations in TET2 are common in myelodysplastic syndromes Langemeijer, S.
 2009
 33 S1 p. S88-S89
2 p.
 artikel
68 P077 Adaptation and changes in quality of life in patients with myelodysplastic syndrome Oliva, E.
 2009
 33 S1 p. S103-
1 p.
 artikel
69 P070 A diagnostic dilemma in a RARS with thrombocytosis and Jak2 negative case – case report Colita, A.
 2009
 33 S1 p. S100-
1 p.
 artikel
70 P083 A father and his son presenting with cytopenias associated with CD3 T large granular lymphocyte proliferation Stalika, E.
 2009
 33 S1 p. S106-
1 p.
 artikel
71 P026 A limited benefit of isolated 5q deletion on prognosis – results of a long term retrospective analysis Cermak, J.
 2009
 33 S1 p. S72-S73
2 p.
 artikel
72 P136 Allogenic stem cell transplant in MDS: results of the Spanish registry Lopez-Villar, O.
 2009
 33 S1 p. S138-S139
2 p.
 artikel
73 P102 A multi-center, open label study evaluating the efficacy of iron chelation therapy with deferasirox in transfusional iron overload patients with myelodysplastic syndromes or aplastic anemia using quantitative R2 MRI Min, Y.
 2009
 33 S1 p. S118-S119
2 p.
 artikel
74 P087 Analysis of iron homeostasis and erythroid activity in a cohort of low-risk myelodysplastic patients Messa, E.
 2009
 33 S1 p. S108-S109
2 p.
 artikel
75 P139 A phase I biological study of azacitidine (Vidaza) to determine the optimal biological dose and route of administration Yang, A.S.
 2009
 33 S1 p. S140-
1 p.
 artikel
76 P134 A phase II pilot study of sorafenib in patients with myelodysplastic syndromes de Castro, C.
 2009
 33 S1 p. S137-
1 p.
 artikel
77 P129 A pilot study of decitabine in combination with arsenic trioxide for patients with myelodysplastic syndromes de Castro, C.
 2009
 33 S1 p. S134-
1 p.
 artikel
78 P057 Apoptosis and telomere length in radiationassociated myelodysplastic syndrome Bazyka, D.
 2009
 33 S1 p. S92-
1 p.
 artikel
79 P037 Apoptotic CD11bdimCD16pos neutrophil subpopulation represents a pitfall in pattern recognition of neutrophil differentiation by flow cytometry in myelodysplastic syndromes Alhan, C.
 2009
 33 S1 p. S79-S80
2 p.
 artikel
80 P125 A single cycle of azacitidine induces complete remission in a case of relapsed acute myeloid leukaemia (AML) Stauder, R.
 2009
 33 S1 p. S132-
1 p.
 artikel
81 P099a The myelodysplastic syndromes (MDS): Is bone marrow examination always necessary? Carmi, G.
 2009
 33 S1 p. S117-
1 p.
 artikel
82 P007 Attempts to define a No Risk subgroup in MDS by examining relative survival in well known scoring systems Noesslinger, T.
 2009
 33 S1 p. S61-S62
2 p.
 artikel
83 P116 Azacitidine for the treatment of lower risk myelodysplastic syndromes: final results from an Italian named patient program Musto, P.
 2009
 33 S1 p. S127-
1 p.
 artikel
84 P090 5-Azacytidine dependent disappearance of 20q myelodysplastic clone: a case report Tatarelli, C.
 2009
 33 S1 p. S111-
1 p.
 artikel
85 P044 Bone marrow activated immune effectors and CD4 CD25highFoxp3 lymphocytes (T Reg) identify distinct subgroups of low and int-1 risk myelodysplastic patients Alfinito, F.
 2009
 33 S1 p. S83-S84
2 p.
 artikel
86 P060 CD34+ marrow cells from MDS patients are characterized by higher levels of intracellular reactive oxygen species and inadequate antioxidant defences Voukelatou, G.
 2009
 33 S1 p. S93-S94
2 p.
 artikel
87 P104 Change in liver iron concentration (LIC), serum ferritin (SF) and labile plasma iron (LPI) over 1 year of deferasirox (Exjade®) therapy in a cohort of patients with MDS Greenberg, P.L.
 2009
 33 S1 p. S120-
1 p.
 artikel
88 P059 Changes in the level of intracellular reactive oxygen species in the hematopoietic progenitors of MDS and AML patients Chan, L.
 2009
 33 S1 p. S93-
1 p.
 artikel
89 P075 Characteristics of patients with therapy-related myelodysplastic syndrome Belohlavkova, P.
 2009
 33 S1 p. S102-
1 p.
 artikel
90 P084 Clinical and cytogenetics findings in secondary myelodysplastic syndromes (MDS) – experience from a single institution in Brazil Tanizawa, R.
 2009
 33 S1 p. S106-S107
2 p.
 artikel
91 P048 Clinical significance of WT1mRNA expression and anti-WT1 antibodies in peripheral blood from myelodsplastic syndrome patients Tamura, H.
 2009
 33 S1 p. S86-
1 p.
 artikel
92 P040 Clinical utility of multiparameter flow cytometry in the diagnosis of 1013 patients with suspected myelodysplastic syndrome: correlation to cytomorphology, cytogenetic, and clinical data Kern, W.
 2009
 33 S1 p. S81-S82
2 p.
 artikel
93 P024 Computerized nuclear texture analysis for the characterization of atypic immature cells in MDS Lorand-Metze, I.
 2009
 33 S1 p. S71-S72
2 p.
 artikel
94 P061 Concordant regulation of estrogen receptor, fat metabolism and osteocalcin in myelodysplastic syndromes Karlic, H.
 2009
 33 S1 p. S94-
1 p.
 artikel
95 P055 Cyclooxygenase-2 is overexpressed in del5q myelodysplastic syndromes Shapiro, R.
 2009
 33 S1 p. S90-S91
2 p.
 artikel
96 P042 Cytogenetic and morphologic features of myelodysplastic syndrome with less than 5 blasts to delineate idiopathic cytopenia with undetermined significance Ohyashiki, K.
 2009
 33 S1 p. S82-S83
2 p.
 artikel
97 P005 Data from the registry of the patients with myelodysplastic syndrome from Clinic of Hematology, Fundeni Clinical Institute, Bucharest, Romania. V. A comparative analysis: from FAB to WHO classification Vasilache, D.
 2009
 33 S1 p. S60-S61
2 p.
 artikel
98 P008 Data from the registry of the patients with myelodysplastic syndrome in a Romanian single center. Analysis of the group under 50 years old Gologan, R.
 2009
 33 S1 p. S62-
1 p.
 artikel
99 P119 Decitabine followed by allogeneic stem cell transplant. Case report Klein, G.
 2009
 33 S1 p. S128-S129
2 p.
 artikel
100 P120 Decitabine in myelodysplastic syndromes, 18 months of follow up: Argentine initial multi-institutional clinical experience Iastrebner, M.
 2009
 33 S1 p. S129-
1 p.
 artikel
101 P123 Decitabine was effective in MDS patients but extreme caution to the patients with trisomy 8 and normo- or hypocellular marrow should be needed Jang, J.
 2009
 33 S1 p. S131-
1 p.
 artikel
102 P038 Decreased expression of CD62L, CD54 and CXCR4 in CD34pos cells adds to the pro-apoptotic profile in low risk and myelodysplastic syndromes Alhan, C.
 2009
 33 S1 p. S80-
1 p.
 artikel
103 P105 Decrease in intra- and extra-cellular free iron species and oxidative stress parameters and increase in serum and urinary hepcidin during treatment with deferasirox in iron-loaded patients with MDS Ghoti, H.
 2009
 33 S1 p. S120-S121
2 p.
 artikel
104 P050 Deferasirox is the only iron chelator inducing NF-kB inhibition in myelodysplastic patients and in leukemic cell lines and acts independently from reactive oxygen species reduction Messa, E.
 2009
 33 S1 p. S87-S88
2 p.
 artikel
105 P101 Deferiprone as a second line treatment in myelodysplastic syndromes. Case report Iastrebner, M.
 2009
 33 S1 p. S118-
1 p.
 artikel
106 P071 Derivative (1;7)(q10;p10) in two patients after autologous hematopoietic cell transplantation (AHCT) Athanasiadou, A.
 2009
 33 S1 p. S100-
1 p.
 artikel
107 P098 Detection and management of iron overload in MDS: a European survey Fenaux, P.
 2009
 33 S1 p. S116-
1 p.
 artikel
108 P047 Determining of intensity methylation in the area of promoter gene P15INK4B as prognostic marker in patients with myelodysplastic syndromes (MDS) Cechova, H.
 2009
 33 S1 p. S85-
1 p.
 artikel
109 P034 Diagnostic relevance of bone marrow leukocytes immunophenotypic analysis in patients with low risk MDS Vikentiou, M.
 2009
 33 S1 p. S77-S78
2 p.
 artikel
110 P036 Diagnostic utility of flow cytometry in myelodysplastic syndromes lacking conventional diagnostic markers: a prospective validation study Ogata, K.
 2009
 33 S1 p. S79-
1 p.
 artikel
111 P014 Differences in the distribution of subtypes according to the WHO classification 2008 between Japanese and German patients with refractory anemia according to the FAB classification in myelodysplastic syndromes Araseki, K.
 2009
 33 S1 p. S66-
1 p.
 artikel
112 P097 Disease burden and treatment impact associated with myelodysplastic syndromes: initial estimates 2009
 33 S1 p. S115-S116
2 p.
 artikel
113 P063 DNA damage in peripheral blood cells of MDS patients Watson, D.
 2009
 33 S1 p. S95-S96
2 p.
 artikel
114 P078 Does Helicobacter pylori infection participate in the pathogenesis of myelodysplastic syndromes (MDS)? Diamantidis, M.
 2009
 33 S1 p. S103-S104
2 p.
 artikel
115 P141 Efficacy and safety of deferasirox (Exjade®) in chelation-naive and previously chelated patients with transfusion-dependent myelodysplastic syndromes (MDS) Schmid, M.
 2009
 33 S1 p. S141-S142
2 p.
 artikel
116 P085 Efficacy of hypomethylating agents on rheumatologic manifestations in high risk myelodysplastic syndromes: first report of a potential indication for this emerging therapy Reutenauer, S.
 2009
 33 S1 p. S107-S108
2 p.
 artikel
117 P135 Efficacy of rituximab on peripheral thrombopenia in low risk myelodysplastic syndrome Sorin, L.
 2009
 33 S1 p. S137-S138
2 p.
 artikel
118 P067 Eltrombopag does not enhance proliferation of non-megakaryocytic leukemia and lymphoma cell lines Erickson-Miller, C.
 2009
 33 S1 p. S98-
1 p.
 artikel
119 P002 Epidemiological characteristics of MDS in Poland in 2008 Dwilewicz-Trojaczek, J.
 2009
 33 S1 p. S59-
1 p.
 artikel
120 P064 Erythropoietin and iron overload as opposite regulators of hepcidin expression Krijt, J.
 2009
 33 S1 p. S96-S97
2 p.
 artikel
121 P015 European LeukemiaNet registry programme for low/INT-1 IPSS score myelodysplastic syndromes Bowen, D.
 2009
 33 S1 p. S66-S67
2 p.
 artikel
122 P088 Evaluation of cardiac iron overload by cardiac MRI T2 in regularly transfused MDS Pascal, L.
 2009
 33 S1 p. S109-
1 p.
 artikel
123 P066 Familiar occurrence of myelodysplastic sydrome with del(5q) Napoleone, L.
 2009
 33 S1 p. S97-S98
2 p.
 artikel
124 P025 Gain of 1q as a potential adverse prognostic marker in myelodysplastic syndrome Lee, D.S.
 2009
 33 S1 p. S72-
1 p.
 artikel
125 P112 Gene expression patterns in MDS with del5q before and during lenalidomide treatment Oliva, E.
 2009
 33 S1 p. S124-
1 p.
 artikel
126 P013 Hellenic national registry of myelodysplastic and bone marrow failure syndromes (EAKMYS): report of 18 months of activity Symeonidis, A.S.
 2009
 33 S1 p. S65-
1 p.
 artikel
127 P082 Hematological manifestations and histopathological findings in T-large granular lymphocyte leukemia Marinos, L.
 2009
 33 S1 p. S105-S106
2 p.
 artikel
128 P091 Hemoglobin has the greatest impact on quality of life (QOL) in MDS patients – a tertiary care cross sectional and longitudinal study Buckstein, R.
 2009
 33 S1 p. S111-S112
2 p.
 artikel
129 P106 High-dose rHuEPO for the treatment of patients with low-risk myelodysplastic syndromes Latagliata, R.
 2009
 33 S1 p. S121-
1 p.
 artikel
130 P018 Host related features explain heterogeneity in risk groups of disease related scoring systems in MDS Pfeilstoecker, M.
 2009
 33 S1 p. S68-
1 p.
 artikel
131 P094 Impact of an educational program at the onset of new therapy (hypomethylating agent) in myelodysplastic syndromes: a pilot study with positive effects on both patients and physicians Moulis, G.
 2009
 33 S1 p. S114-
1 p.
 artikel
132 P035 Improvement in cytogenetic diagnosis and clinical prognostication using SNP-A karyotyping in combination with metaphase cytogenetics in MDS, MDS/MPD and secondary AML Tiu, R.V.
 2009
 33 S1 p. S78-S79
2 p.
 artikel
133 P009 Incidence and prevalence of myelodysplastic syndromes (MDS) in Duesseldorf 1996–2005 Schoonen, W.
 2009
 33 S1 p. S62-S63
2 p.
 artikel
134 P074 Incidence of HFE gene mutations in Chinese patients with myelodysplastic syndromes and aplastic anemia Xiao, Z.
 2009
 33 S1 p. S101-
1 p.
 artikel
135 P004 Incidence of myelodysplastic syndrome in Western Pennsylvania Taioli, E.
 2009
 33 S1 p. S60-
1 p.
 artikel
136 P011 Incidence of myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) in Norway 1993–2006 Schoonen, W.
 2009
 33 S1 p. S64-
1 p.
 artikel
137 P012 Incidence of myelodysplastic syndromes (MDS) in the geographically defined area of south-western Greece Avgerinou, C.
 2009
 33 S1 p. S64-S65
2 p.
 artikel
138 P069 Incidence of preexisting organ damage in myelodysplastic syndromes (MDS) patients without a history of chronic red blood cell (RBC) transfusion Wong, L.
 2009
 33 S1 p. S99-
1 p.
 artikel
139 P079 Increase in bone marrow immature nonlymphoid early precursors are indicative of a short survival in myelodysplastic syndromes Lorand-Metze, I.
 2009
 33 S1 p. S104-
1 p.
 artikel
140 P100 Indications for iron chelation therapy – the Budapest Study Group protocol proposal Varkonyi, J.
 2009
 33 S1 p. S117-S118
2 p.
 artikel
141 P099 Influence of RBC transfusions on clinical outcomes among USA Medicare beneficiaries with newly diagnosed myelodysplastic syndromes Goldberg, S.L.
 2009
 33 S1 p. S116-
1 p.
 artikel
142 P058 Intracellular ROS in bone marrow cells in myelodysplastic syndrome: technical and methodological considerations Chan, L.
 2009
 33 S1 p. S92-S93
2 p.
 artikel
143 P133 In vitro and in vivo study of treatment with the HDAC inhibitor valproic acid (VPA) in two patients affected by acute myeloid leukaemia post myelodysplastic syndrome Tatarelli, C.
 2009
 33 S1 p. S136-S137
2 p.
 artikel
144 P103 Iron chelation treatment in patients with myelodysplastic syndromes (MDS): the experience of the Hellenic MDS Study Group Kouraklis, A.
 2009
 33 S1 p. S119-S120
2 p.
 artikel
145 P092 Iron overload and haematopoiesis in MDS: Does blood transfusion promote progression to AML? Chan, L.
 2009
 33 S1 p. S112-S113
2 p.
 artikel
146 P089 Is idiopathic cytopenia of undetermined significance (ICUS) a valid clinical concept? A longitudinal clinicopathological study Hanson, C.
 2009
 33 S1 p. S109-S111
3 p.
 artikel
147 P033 Isolated del 20q defines a subgroup of MDS patients with lower blast counts and more frequent thrombocytopenia Braun, T.
 2009
 33 S1 p. S77-
1 p.
 artikel
148 P053 JAK2 V617F mutation in primary myelodysplastic syndromes: a multicenter retrospective study Dahabreh, I.
 2009
 33 S1 p. S89-
1 p.
 artikel
149 P032 Karyotypic complexity and multiclonality: two cytogenetic parameters to be considered in MDS prognostic evaluation Gourgouveli, E.
 2009
 33 S1 p. S77-
1 p.
 artikel
150 P076 Laboratory features of mixed myelodysplastic syndrome associated with B-thalassemia intermedia Gologan, R.
 2009
 33 S1 p. S102-S103
2 p.
 artikel
151 P110 Lenalidomide in low and int-1 risk MDS with del5q: efficacy and quality of life Oliva, E.
 2009
 33 S1 p. S123-
1 p.
 artikel
152 P093 Link between occupational exposure to heavy metals and high risk myelodysplastic syndromes Divies, A.
 2009
 33 S1 p. S113-S114
2 p.
 artikel
153 P003 Literature review on the epidemiology of myelodysplastic syndrome (MDS) Taioli, E.
 2009
 33 S1 p. S60-
1 p.
 artikel
154 P108 Long-term outcome of low-risk MDS patients treated with ESAs: an update of the GFM cohort Kelaidi, C.
 2009
 33 S1 p. S122-S123
2 p.
 artikel
155 P111 Long-term outcome of MDS with del 5q before the lenalidomide era. The GFM experience Kelaidi, C.
 2009
 33 S1 p. S124-
1 p.
 artikel
156 P115 Long-term transfusion independence in del(5q) patients despite discontinuation of lenalidomide Giagounidis, A.
 2009
 33 S1 p. S126-S127
2 p.
 artikel
157 P132 Low-dose melphalan in patients with intermediate or high-risk myelodysplastic syndromes Xiao, Z.
 2009
 33 S1 p. S136-
1 p.
 artikel
158 P023 Lymphoid micromegakarycytes is a unfavourable prognostic factor in patients with primary myelodysplastic syndromes Xiao, Z.
 2009
 33 S1 p. S71-
1 p.
 artikel
159 P124 Matched pair analysis of conventional regimens versus hypomethylating agents for the treatment of higher-risk myelodysplastic syndromes – an analysis from the Duesseldorf MDS Registry Kuendgen, A.
 2009
 33 S1 p. S131-
1 p.
 artikel
160 P031 MDS. Results of cytogenetic analysis in 315 patients studied in Instituto Hematologico de Occidente (IHO), Maracaibo, Venezuela Macias-Duerto, M.
 2009
 33 S1 p. S76-
1 p.
 artikel
161 P054 MicroRNA expression profiling of high and low risk MDS Gaken, J.
 2009
 33 S1 p. S90-
1 p.
 artikel
162 P117 Monocentric evaluation of response and tolerability of subcutaneous azacitidine in elderly MDS patients with comorbidities Santini, V.
 2009
 33 S1 p. S127-S128
2 p.
 artikel
163 P080 Myelodysplastic syndromes (MDS): factors increasing probability for leukaemic transformation in a Greek series of patients from a single institution Diamantidis, M.
 2009
 33 S1 p. S104-
1 p.
 artikel
164 P010 Myelodysplastic syndromes, pilot register, first results. Grupo de Estudio de Sindromes Mielodisplasicos. Sociedad Argentina de Hematologia Prates, M.
 2009
 33 S1 p. S63-S64
2 p.
 artikel
165 24 PNH: new options Hill, A.
 2009
 33 S1 p. S20-S21
2 p.
 artikel
166 P062 Overexpansion of Th17 and Th1/17 cells in patients with myelodysplastic syndromes Solomou, E.
 2009
 33 S1 p. S95-
1 p.
 artikel
167 P056 Pathophysiology of patients with myelodysplastic syndrome (MDS) over the age of 80 Wong, L.
 2009
 33 S1 p. S91-S92
2 p.
 artikel
168 P121 Patients with hematologic disorders receiving azacitidine who are enrolled in AVIDA, a longitudinal patient registry, achieve transfusion independence Grinblatt, D.
 2009
 33 S1 p. S129-S130
2 p.
 artikel
169 P086 Pediatric myelodysplastic syndrome in a family with mitochondrial DNA mutations De Vries, A.
 2009
 33 S1 p. S108-
1 p.
 artikel
170 P131 Phase I trial of the combination of the epigenetic modulators vorinostat and azacitidine (azaC) in patients with the myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). An update from the NY Cancer Consortium Silverman, L.
 2009
 33 S1 p. S135-S136
2 p.
 artikel
171 P049 PIG-A mutations during evolution of MDS to AML Efthymiou, A.
 2009
 33 S1 p. S86-S87
2 p.
 artikel
172 P041 Potential value of flow cytometry immunophenotyping in the diagnosis of hypoplastic MDS Font, P.
 2009
 33 S1 p. S82-
1 p.
 artikel
173 P065 Profile of metabolism-related cytokines in myelodysplastic syndromes Matsouka, P.
 2009
 33 S1 p. S97-
1 p.
 artikel
174 P001 Prognostic factors in patients with refractory anemia with excess of blasts (RAEB) reclassified according to WHO proposal Breccia, M.
 2009
 33 S1 p. S59-
1 p.
 artikel
175 P030 Prognostic impact on survival of an unsuccessful conventional cytogenetic study in patients with myelodysplastic syndromes (MDS) Cervera, J.
 2009
 33 S1 p. S75-S76
2 p.
 artikel
176 P029 Prognostic relevance of specific chromosomal abnormalities in chronic myelomonocytic leukemia Such, E.
 2009
 33 S1 p. S74-S75
2 p.
 artikel
177 P021 Prognostic significance of beta 2 microglobulin predicting survival in patients with myelodysplastic syndromes Galanopoulos, A.
 2009
 33 S1 p. S70-
1 p.
 artikel
178 P027 Prognostic significance of less frequent or rare chromosome abnormalities in Greek patients with myelodysplastic syndromes Manola, K.
 2009
 33 S1 p. S73-S74
2 p.
 artikel
179 P127 Rates of infection and bleeding are not increased in patients (Pts) with MDS treated with azacitidine (AZA) compared with best supportive care (BSC) Santini, V.
 2009
 33 S1 p. S133-
1 p.
 artikel
180 P140 Reduction in serum ferritin (SF) is associated with improvement in liver transaminase levels during treatment with deferasirox (Exjade®) in ironoverloaded patients with myelodysplastic syndromes (MDS) Gattermann, N.
 2009
 33 S1 p. S140-S141
2 p.
 artikel
181 P020 Refining prognostic systems by comorbidity: are existing scores sufficient for MDS or may specific scores perform better? Makrai, A.
 2009
 33 S1 p. S69-S70
2 p.
 artikel
182 P109 Results of phase II clinical study of lenalidomide in Japanese patients with myelodysplastic syndrome (MDS) Harada, H.
 2009
 33 S1 p. S123-
1 p.
 artikel
183 P016 Revised WHO 2008 classification of patients with RCUD (refractory cytopenia with unilineage dysplasia) Breccia, M.
 2009
 33 S1 p. S67-
1 p.
 artikel
184 P095 Risk factors and outcome of severe infectious or hemorrhagic events during the course of myelodysplastic syndromes Challan-Belval, T.
 2009
 33 S1 p. S114-S115
2 p.
 artikel
185 P072 Secondary acute myeloid leukemia (AML) associated with monosomy 7 in two patients with severe aplastic anemia Athanasiadou, A.
 2009
 33 S1 p. S100-S101
2 p.
 artikel
186 P022 Serum CD44 levels predict survival in patients with low-risk myelodysplastic syndromes Stauder, R.
 2009
 33 S1 p. S71-
1 p.
 artikel
187 P137 Supporting MDS patients in a regional hospital setting Chimonas, T.
 2009
 33 S1 p. S139-
1 p.
 artikel
188 P068 Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndrome Boehrer, S.
 2009
 33 S1 p. S98-S99
2 p.
 artikel
189 P028 Survival, prognostic factors, and leukemic transformation in a multicenter study of 241 patients with MDS and del(5q) Germing, U.
 2009
 33 S1 p. S74-
1 p.
 artikel
190 P045 TET2 gene harbors mutations associated with myeloid malignancies Jankowska, A.M.
 2009
 33 S1 p. S84-
1 p.
 artikel
191 P051 TET2 is a tumor suppressor gene targeted in myeloid disorders Delhommeau, F.
 2009
 33 S1 p. S88-
1 p.
 artikel
192 P118 The capacity of the hypomethylating agents azacytidine and decitabine to induce apoptosis and cell cycle arrest depends on the activation of the DNA-damage response pathway Boehrer, S.
 2009
 33 S1 p. S128-
1 p.
 artikel
193 P039 The diagnostic utility of bone marrow flow-cytometric immunophenotyping for the differential diagnosis of chronic idiopathic neutropenia from myelodysplastic syndromes Papadaki, H.
 2009
 33 S1 p. S80-S81
2 p.
 artikel
194 P006 The incidence and overall survivall in MDS – epidemiological aspects Rosca, A.
 2009
 33 S1 p. S61-
1 p.
 artikel
195 P081 The questions on megakaryopoiesis in MDS patients with del(5q) Neuwirtova, R.
 2009
 33 S1 p. S105-
1 p.
 artikel
196 P019 Time changes in predictive power of established and recently proposed clinical, cytogenetic, and co-morbidity scores in MDS Tuechler, H.
 2009
 33 S1 p. S68-S69
2 p.
 artikel
197 P128 Transfusion independence (TI) in patients with myelodysplastic syndromes (MDS) treated with azacitidine (AZA) Silverman, L.
 2009
 33 S1 p. S133-S134
2 p.
 artikel
198 P122 Treatment of CMML by azacytidine (AZA): a preliminary report on 23 patients (pts) Wolfromm, W.
 2009
 33 S1 p. S130-
1 p.
 artikel
199 P130 Treatment of intermediate and high risk myelodysplastic syndrome patients with azacitidine. The Hellenic experience Pappa, V.
 2009
 33 S1 p. S134-S135
2 p.
 artikel
200 P114 Treatment of lower risk MDS with del 5q by lenalidomide (LEN), with or without G-CSF: current results of the French Patient Named Program (ATU) Sebert, M.
 2009
 33 S1 p. S125-S126
2 p.
 artikel
201 P107 Treatment of MDS with moderate anemia, not requiring RBC transfusions, by erythropoiesis stimulating agents (ESAs) Park, S.
 2009
 33 S1 p. S122-
1 p.
 artikel
202 P126 Treatment of progression of myeloproliferative neoplasm (MPN) to MDS/AML by azacytidine (AZA): a report on 44 patients (pts) Thepot, S.
 2009
 33 S1 p. S132-S133
2 p.
 artikel
203 P073 Treatment-related AML/MDS in multiple myeloma Vadikoliou, C.
 2009
 33 S1 p. S101-
1 p.
 artikel
204 P113 Treatment with lenalidomide for patients with myelodysplastic syndromes (MDS): report of the Hellenic experience on 73 patients. A retrospective analysis of the Hellenic MDS Study Group Symeonidis, A.
 2009
 33 S1 p. S125-
1 p.
 artikel
205 P138 Valproic acid at therapeutic plasma levels may increase 5-azacitidine efficacy in higher risk myelodysplastic syndromes Voso, M.
 2009
 33 S1 p. S139-S140
2 p.
 artikel
206 P096 Varicella-zoster virus meningoencephalitis during the course of hypomethylating agent therapy in high risk myelodysplastic syndrome Challan-Belval, T.
 2009
 33 S1 p. S115-
1 p.
 artikel
207 P017 WPSS versus Simplified Myelodysplastic Syndrome Risk Score: which is the best tool for prediction of survival in myelodysplastic patients? Breccia, M.
 2009
 33 S1 p. S67-
1 p.
 artikel
208 11 Real-time prognostic evaluation in MDS Malcovati, L.
 2009
 33 S1 p. S8-S9
2 p.
 artikel
209 42 Reducing the frequency of relapse after hematopoietic cell transplantation for MDS Deeg, H.J.
 2009
 33 S1 p. S28-S29
2 p.
 artikel
210 20 Refractory anemia with ringed sideroblasts associated with marked thrombocytosis Cazzola, M.
 2009
 33 S1 p. S15-S16
2 p.
 artikel
211 22 Refractory cytopenia of childhood: separating AA and inherited bone marrow failure disorders – results of therapy Niemeyer, C.M.
 2009
 33 S1 p. S17-S18
2 p.
 artikel
212 34 Should we use histone deacetylase inhibitors in the treatment of MDS? Yang, A.S.
 2009
 33 S1 p. S26-
1 p.
 artikel
213 5 Telomere biology and the pathogenesis of clonal evolution from bone marrow failure Young, N.S.
 2009
 33 S1 p. S2-
1 p.
 artikel
214 25 The basics: iron overload Hershko, C.
 2009
 33 S1 p. S21-S22
2 p.
 artikel
215 35 Thrombopoietic growth factors Sekeres, M.
 2009
 33 S1 p. S26-
1 p.
 artikel
216 12 Updated cytogenetic risk features in MDS – present state Haase, D.
 2009
 33 S1 p. S9-S10
2 p.
 artikel
217 13 Update of cytogenetic risk factors in MDS (Part II): a strategy to incorporate fluorescence in situ hybridization (FISH) and “FISH on a Chip” (aCGH) results in future clinical trials for the myelodysplastic syndromes (MDS) Slovak, M.L.
 2009
 33 S1 p. S10-
1 p.
 artikel
218 YI3 De novo and familial myelodysplastic syndromes in the Greek Paediatric Registry. Clinical course and correlation with congenital disorders other than marrow failure Makis, A.
 2009
 33 S1 p. S56-S57
2 p.
 artikel
219 YI2 Diagnostic utility of a small four color panel for flow cytometric analysis in myelodysplastic syndromes Reis-Alves, S.
 2009
 33 S1 p. S55-
1 p.
 artikel
220 YI4 Different patterns of telomerase reverse transcriptase (hTERT) mRNA variant expression profiles in patients with myelodysplastic syndromes Verrou, E.
 2009
 33 S1 p. S57-
1 p.
 artikel
221 YI1 Gene expression profiling of day 7 erythroblasts from refractory anemia with ringed sideroblasts (RARS) and microarray-based identification of erythroid granulocyte-CSF (G-CSF) targets Nikpour, M.
 2009
 33 S1 p. S55-
1 p.
 artikel
222 YI6 Mutations of E3 ubiquitin ligase Cbl family members constitute a novel common pathogenic lesion in myelodysplastic syndromes Makishima, H.
 2009
 33 S1 p. S58-
1 p.
 artikel
223 YI5 Proteasome proteolytic activity in marrow CD34+ and peripheral blood mononuclear cells, from patients with MDS Karabina, S.
 2009
 33 S1 p. S57-S58
2 p.
 artikel
                             223 gevonden resultaten
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland